Skip to main content
Clinical Trials/KCT0002383
KCT0002383Completed未知

A Randomized, Open-label, Single dose, 3-Treatment, 3-Period Williams-Design to Assess the Pharmacokinetic Characteristics and Food Effect of Levodropropizine Controlled-Release Tablets Compared with Levodropropizine Immediate-Release Tablets in Healthy Male Subjects

Korea United Pharm0 sites48 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
48

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional Study

Eligibility Criteria

Ages
20(Year) to 55(Year) (—)
Sex
Male

Inclusion Criteria

  • 1. Healthy male volunteer in the age of 20-55
  • 2. Body weight = 55 kg and in the range of calculated IBW(Ideal Body Weight) ±20%
  • 3. Subject without a hereditary problems, chronic disease and morbid symptom
  • 4. Suitable clinical laboratory test values
  • 5. Subject who sign on an informed consent form willingly

Exclusion Criteria

  • 1. History of significant hypersensitivity reaction of levodropropizine or anti-tussive drugs
  • 2. Sitting systolic blood pressure = 145 mmHg or< 95 mmHg, sitting diastolic blood pressure = 100 mmHg or < 50 mmHg, pulse = 100 beats per minute
  • 3. Clinically significant disease with hepatobiliary, nephrological, neurologic, respiratory, haemato-oncological, endocrine, urogenital, psychiatric, musculoskeletal, immune, otorhinolaryngological, cardiovascular system
  • 4. Galactose intolerance
  • 5. Significant cardiac arrhythmia, QT prolongation (>450 m/sec)
  • 6. Gastrointestinal disease or gastrointestinal surgery
  • 7. Medical history gastric ulcer or gastric hemorrhage within 2 months
  • 8. Continuously taking Alcohol > 21 units/week, Cigarette > 10 cigarettes/day
  • 9. Subject treated Investigational product(include Bioequivalence test) within 3 months
  • 10. Whole blood donation within 2 months, component blood donation or blood transfusion within 1 month
  • 11. Subject treated metabolizing enzyme inducers or inhibitors within 1 month
  • 12. Subject treated ethical the counter or herbal medicine within 2 weeks, weeks, over-the-counter or vitamin within 1 week
  • 13. Psychological disease, alcoholism
  • 14. Another clinical condition in judgement of investigator
  • 15. Subject treated grapefruit juice within 1 week
  • 16. Drug abuse

Investigators

Sponsor
Korea United Pharm

Similar Trials

Recruiting
Not Applicable
A randomized, open-label, single dose, 3-treatment, 3-period, 6-sequence crossover study to investigate the effect of food on the pharmacokinetics/pharmacodynamics and safety of CKD-519 after oral administration in healthy adult volunteersEndocrine, nutritional and metabolic disease
KCT0001545Chong Kun Dang42
Completed
Not Applicable
A single-dose, 3-treatment, 3-period, 6-sequence crossover study in healthy male subjects to evaluate the pharmacokinetics of GLA5PR GLARS-NF1 tablet 150mg and LYRICA® capsule 75mgEndocrine, nutritional and metabolic disease
KCT0001311GL PharmTech30
Completed
Not Applicable
A study to compare the pharmacokinetics and safety/tolerability of BS-105 enteric-coated tablet A” or BS-105 enteric-coated tablet B” of Bio-Synectics to original drug in healthy male subjects (Pilot study)Certain infectious and parasitic diseases
KCT0004007Bio-Synectics9
Completed
Not Applicable
A clinical study to compare pharmacokinectic characteristics of Eperisone Hydrochloride and Aceclofenac with HCP1104 treatment to those of co-administration of Eperisone Hydrochloride 50mg tablet and Aceclofenac 100mg tablet in healthy adult male volunteers
KCT0000907Hanmi Pharm30
Not yet recruiting
Not Applicable
A randomized, open-label, single dose, three-way crossover clinical trial to investigate the pharmacokinetics incorporating a comparison of fed/fasted pharmacokinetics of HIP1402 in healthy male volunteersDiseases of The genitoruinary system
KCT0001610Hanmi Pharm24